Bristol-Myers Squibb (BMY) Financials: History & Chart

Bristol-Myers Squibb Company (BMY)BMYBristol-Myers Squibb Company

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher S. Boerner

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	48.48B	11.49B	12.50B	12.22B	12.27B	11.20B	12.34B	11.89B	12.20B
Cost of Goods Sold	15.15B	3.42B	4.10B	3.44B	4.20B	3.86B	4.92B	5.28B	5.40B
Gross Profit	33.33B	8.07B	8.40B	8.79B	8.07B	7.34B	7.42B	6.62B	6.80B
Gross Profit Margin	68.7%	70.2%	67.2%	71.9%	65.8%	65.5%	60.2%	55.6%	55.7%
Total Operating Expenses	20.88B	4.80B	6.99B	5.15B	3.95B	3.82B	4.89B	4.33B	4.22B
Research & Development	10.03B	2.65B	2.59B	2.53B	2.26B	2.24B	2.79B	2.35B	2.29B
Selling, General & Administrative	7.28B	1.62B	2.18B	1.79B	1.69B	1.58B	1.85B	1.98B	1.92B
Operating Income (EBIT)	12.45B	3.27B	1.42B	3.64B	4.12B	3.52B	2.53B	2.29B	2.58B
Operating Margin	25.7%	28.5%	11.4%	29.8%	33.6%	31.4%	20.5%	19.2%	21.2%
Income Before Tax (EBT)	9.60B	3.24B	1.47B	3.11B	1.77B	2.97B	175.00M	1.68B	1.29B
Interest Income	300.00M	N/A	N/A	161.00M	139.00M	N/A	N/A	N/A	N/A
Interest Expense	1.02B	N/A	51.00M	480.00M	485.00M	494.00M	496.00M	505.00M	521.00M
Other Income/Expense	-2.85B	-31.00M	51.00M	-525.00M	-2.34B	-550.00M	-2.36B	-612.00M	-1.30B
Net Income	7.28B	2.68B	1.09B	2.20B	1.31B	2.46B	72.00M	1.21B	1.68B
Income Tax Expense	2.32B	561.00M	384.00M	919.00M	460.00M	509.00M	99.00M	461.00M	-398.00M
Net Profit Margin	15.0%	23.3%	8.7%	18.0%	10.7%	21.9%	0.6%	10.2%	13.8%
EBITDA	15.73B	3.71B	2.25B	4.63B	5.15B	4.53B	4.41B	4.88B	5.18B
EBITDA Margin	32.4%	32.3%	18.0%	37.9%	41.9%	40.5%	35.7%	41.0%	42.5%
Depreciation & Amortization	3.29B	437.00M	826.00M	993.00M	1.03B	1.01B	1.88B	2.59B	2.60B
EPS Basic	3.56	1.31	0.53	1.08	0.64	1.21	0.04	0.60	0.83
EPS Diluted	3.56	1.31	0.53	1.08	0.64	1.20	0.04	0.60	0.83
Shares Outstanding	2.04B	2.04B	2.04B	2.04B	2.04B	2.03B	2.03B	2.03B	2.03B
Diluted Shares Outstanding	2.04B	2.04B	2.04B	2.04B	2.04B	2.04B	2.04B	2.03B	2.03B

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	48.19B	48.30B	45.01B	46.16B	46.38B	42.52B	26.14B	22.56B
Cost of Goods Sold	15.59B	20.87B	19.65B	19.67B	19.62B	20.82B	8.89B	6.49B
Gross Profit	32.60B	27.43B	25.36B	26.49B	26.76B	21.70B	17.25B	16.07B
Gross Profit Margin	67.6%	56.8%	56.3%	57.4%	57.7%	51.0%	66.0%	71.3%
Total Operating Expenses	19.91B	17.77B	16.89B	17.22B	17.22B	17.21B	10.81B	9.68B
Research & Development	9.61B	9.78B	9.21B	9.41B	9.53B	9.56B	5.95B	5.13B
Selling, General & Administrative	7.24B	7.87B	7.68B	7.81B	7.69B	7.65B	4.86B	4.55B
Operating Income (EBIT)	12.70B	9.66B	8.47B	9.27B	9.54B	4.49B	6.44B	6.39B
Operating Margin	26.3%	20.0%	18.8%	20.1%	20.6%	10.6%	24.6%	28.3%
Income Before Tax (EBT)	9.33B	-8.38B	8.44B	7.71B	8.10B	-6.87B	4.97B	5.97B
Interest Income	300.00M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	1.51B	1.95B	1.17B	1.23B	1.33B	1.42B	656.00M	183.00M
Other Income/Expense	-3.37B	-18.04B	-32.00M	-1.56B	-1.44B	-11.36B	-1.46B	-426.00M
Net Income	7.05B	-8.95B	8.03B	6.33B	6.99B	-8.99B	3.44B	4.92B
Income Tax Expense	2.27B	554.00M	400.00M	1.37B	1.08B	2.12B	1.51B	1.02B
Net Profit Margin	14.6%	-18.5%	17.8%	13.7%	15.1%	-21.2%	13.2%	21.8%
EBITDA	16.56B	19.26B	18.23B	19.55B	20.23B	14.87B	8.19B	7.03B
EBITDA Margin	34.4%	39.9%	40.5%	42.3%	43.6%	35.0%	31.3%	31.2%
Depreciation & Amortization	3.86B	9.60B	9.76B	10.28B	10.69B	10.38B	1.75B	637.00M
EPS Basic	3.46	-4.41	3.88	2.97	3.15	-3.98	2.02	3.03
EPS Diluted	3.45	-4.41	3.86	2.95	3.12	-3.98	2.01	3.03
Shares Outstanding	2.04B	2.03B	2.07B	2.13B	2.22B	2.26B	1.71B	1.63B
Diluted Shares Outstanding	2.04B	2.03B	2.08B	2.15B	2.25B	2.26B	1.71B	1.64B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.